Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Gang Wang, Kun Zhao, Caroline Reynaud-Mougin, Henrik Loft, Hongye Ren, Hanne-Lise F. Eriksen & Anders Ettrup. (2020) Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder. Current Medical Research and Opinion 36:5, pages 875-882.
Read now
Read now
Marc Kelliny, Paul E Croarkin, Katherine M Moore & William V Bobo. (2015) Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. Therapeutics and Clinical Risk Management 11, pages 1193-1212.
Read now
Read now
Mayce Al-Sukhni, Nadia A Maruschak & Roger S McIntyre. (2015) Vortioxetine: a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. Expert Opinion on Drug Safety 14:8, pages 1291-1304.
Read now
Read now
Articles from other publishers (16)
Cheolmin Shin, Sang Won Jeon, Seung-Hoon Lee, Chi-Un Pae, Narei Hong, Hyun Kook Lim, Ashwin A. Patkar, Prakash S. Masand, Hyonggin An & Changsu Han. (2023) Efficacy and Safety of Escitalopram, Desvenlafaxine, and Vortioxetine in the Acute Treatment of Anxious Depression: A Randomized Rater-blinded 6-week Clinical Trial. Clinical Psychopharmacology and Neuroscience 21:1, pages 135-146.
Crossref
Crossref
Chris F Johnson, Margaret Maxwell, Brian Williams, Nadine Dougall & Stephen MacGillivray. (2022) Dose-response effects of selective serotonin reuptake inhibitor monotherapy for the treatment of depression: systematic review of reviews and meta-narrative synthesis. BMJ Medicine 1:1, pages e000017.
Crossref
Crossref
Daniela Adamo, Elena Calabria, Noemi Coppola, Giuseppe Pecoraro & Michele Davide Mignogna. (2021) Vortioxetine as a new frontier in the treatment of chronic neuropathic pain: a review and update. Therapeutic Advances in Psychopharmacology 11, pages 204512532110343.
Crossref
Crossref
Gernot Wagner, Marie-Therese Schultes, Viktoria Titscher, Birgit Teufer, Irma Klerings & Gerald Gartlehner. (2018) Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis. Journal of Affective Disorders 228, pages 1-12.
Crossref
Crossref
Estela Salagre, Iria Grande, Brisa Solé, Jose Sanchez-Moreno & Eduard Vieta. (2018) Vortioxetine: A new alternative for the treatment of major depressive disorder. Revista de Psiquiatría y Salud Mental (English Edition) 11:1, pages 48-59.
Crossref
Crossref
Estela Salagre, Iria Grande, Brisa Solé, Jose Sanchez-Moreno & Eduard Vieta. (2018) Vortioxetina: una nueva alternativa en el trastorno depresivo mayor. Revista de Psiquiatría y Salud Mental 11:1, pages 48-59.
Crossref
Crossref
Sidney H. Kennedy, Jean-Marie Grouin, Stéphanie Cadour, Véronique Robert & Françoise Picarel-Blanchot. (2018) Relative short-term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder. Human Psychopharmacology: Clinical and Experimental 33:1, pages e2646.
Crossref
Crossref
Magdalena Sowa-Kućma, Patrycja Pańczyszyn-Trzewik, Paulina Misztak, Rafał R. Jaeschke, Katherine Sendek, Krzysztof Styczeń, Wojciech Datka & Magdalena Koperny. (2017) Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant. Pharmacological Reports 69:4, pages 595-601.
Crossref
Crossref
A.H. Young, L. Evitt, M. Brignone, F. Diamand, K. Atsou, R. Campbell, S. Cure & N. Danchenko. (2017) Cost-utility evaluation of vortioxetine in patients with Major Depressive Disorder experiencing inadequate response to alternative antidepressants in the United Kingdom. Journal of Affective Disorders 218, pages 291-298.
Crossref
Crossref
Louise K. Refsgaard, Kia Haubro, Darryl S. Pickering, Sarah A. Stuart, Emma S. J. Robinson & Jesper T. Andreasen. (2016) Effects of sertraline, duloxetine, vortioxetine, and idazoxan in the rat affective bias test. Psychopharmacology 233:21-22, pages 3763-3770.
Crossref
Crossref
James Lomas, Alexis Llewellyn, Marta Soares, Mark Simmonds, Kath Wright, Alison Eastwood & Stephen Palmer. (2016) The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence. PharmacoEconomics 34:9, pages 901-912.
Crossref
Crossref
Himanshu Naik, Serena Chan, Majid Vakilynejad, Grace Chen, Henrik Loft, Atul R. Mahableshwarkar & Johan Areberg. (2015) A Population Pharmacokinetic–Pharmacodynamic Meta‐Analysis of Vortioxetine in Patients with Major Depressive Disorder. Basic & Clinical Pharmacology & Toxicology 118:5, pages 344-355.
Crossref
Crossref
Leslie Citrome. (2016) Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders 196, pages 225-233.
Crossref
Crossref
. (2016) What role for ▼vortioxetine?:. Drug and Therapeutics Bulletin 54:3, pages 30-33.
Crossref
Crossref
David S Baldwin & Venkatesh Ballagere Hanumanthaiah. (2015) Vortioxetine in the treatment of major depressive disorder. Future Neurology 10:2, pages 79-89.
Crossref
Crossref
Jonathan Smithson & Philip B. Mitchell. 2015. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions
15
31
.